# US 2026/0176309 A1 · Endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0176309 A1
- Document ID: US20260176309A1
- Status: Published application
- Kind: A1
- Application number: 19/065,347
- Filed: 2025-02-27
- Published: 2026-06-25
- Earliest claimed: 2024-02-27
- Assignees: University of Maryland, College Park
- Applicants: University of Maryland, College Park
- Inventors: Daniel C. NELSON; Adit B. ALREJA; Sara Beth LINDEN
- Web page: https://patentgrep.com/patent/US20260176309A1

## CPC

- C07K 14/3156: {from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153)}
- A61K 9/0043: {Nose}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA/DNA) or variants thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(i) a SP-CHAP polypeptide, fragment or variant thereof; or
(ii) a nucleic acid that encodes for the SP-CHAP, fragment or variant thereof,
and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the SP-CHAP protein is a polypeptide of SEQ ID NO:1, a polypeptide having at least about 90% or more homology with the SP-CHAP of SEQ ID NO:1 or a polypeptide fragment thereof that retains endolysin activity.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the nucleic acid is codon optimized.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the SP-CHAP contains a signal peptide.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein administration of the pharmaceutical composition results in a reduction in pneumococcal disease when administered to a subject having a pneumococcal infection.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, further comprising a second therapeutic useful for treatment of the pneumococcal disease.

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5, wherein the pneumococcal disease is selected from the group consisting of pneumonia, invasive pneumococcal disease, meningitis and sepsis.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein SP-CHAP-encoding nucleic acid is associated with a vector.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the SP-CHAP-encoding nucleic acid is associated with a lipid-based composition.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, formulated for intranasal administration.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the SP-CHAP, or SP-CHAP encoding nucleic acid, is associated with a nanoparticle.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the SP-CHAP, or SP-CHAP encoding nucleic acid is associated with a liposome.

### Claim 13 (depends on 1)

A method for treating a pneumococcal disease in a subject infected with a pneumococcal bacterium, the method comprising administering to the subject, an effective amount of the pharmaceutical composition of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pneumococcal disease is selected from the group consisting of pneumonia, invasive pneumococcal disease, meningitis and sepsis.

### Claim 15 (depends on 1, 13)

The method of claim 13, wherein the pharmaceutical composition of claim 1 is co-administered with a second therapeutic useful for treatment of the pneumococcal disease.

### Claim 16 (depends on 13)

The method of claim 13, wherein the second therapeutic is an anti-bacterial agent.

### Claim 17 (depends on 1, 13)

The method of claim 13, wherein the pharmaceutical composition of claim 1 is administered intranasally.

### Claim 18 (depends on 1)

A kit comprising the pharmaceutical composition or claim 1 and instructions for use in treating a pneumococcal disease.
